Muscaritoli Maurizio, Pradelli Lorenzo
Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
AdRes-Health Economics and Outcome Research, Turin, Italy.
Front Nutr. 2021 Aug 2;8:697529. doi: 10.3389/fnut.2021.697529. eCollection 2021.
Available data on the effect of lipid composition of enteral formulas on clinical outcomes are controversial. The present systematic review was performed in order to verify whether the presence of specific lipidic substrates, namely medium-chain triglycerides (MCT), in enteral tube feeding formulas is associated to measurable clinical benefits in patients receiving enteral nutrition in different clinical settings, including home enteral nutrition (HEN). The results of this systematic review highlight a lack of robust evidence supporting the use of specific types of lipids in standard or disease-specific formulas. Evidence exists, however, that MCT-containing formulas are safe and well-tolerated. Further, well-designed, adequately powered, randomized controlled trials would be needed in order to assess the superiority of MCT- containing enteral formulas over other standard or disease-specific commercially available enteral products.
关于肠内营养制剂的脂质成分对临床结局影响的现有数据存在争议。进行本次系统评价是为了验证肠内管饲制剂中特定脂质底物（即中链甘油三酯，MCT）的存在是否与不同临床环境（包括家庭肠内营养，HEN）中接受肠内营养的患者可测量的临床益处相关。该系统评价的结果表明，缺乏有力证据支持在标准或疾病特异性制剂中使用特定类型的脂质。然而，有证据表明含MCT的制剂是安全且耐受性良好的。此外，需要设计良好、有足够效力的随机对照试验，以评估含MCT的肠内制剂相对于其他标准或疾病特异性市售肠内产品的优越性。
